CureVac Announces Promising Interim Data from Seasonal Influenza Vaccine Development Program.

CureVac's seasonal flu vaccine candidate demonstrates promising results in Phase 2 interim data, showing boosted antibody titers for all encoded seasonal influenza strains and exceeding licensed comparator vaccines' titers for influenza A strains. The candidate encodes antigens for all four WHO-recommended flu strains and has an acceptable safety profile. Further optimizations for enhancing immune responses against influenza B strains will be tested in additional Phase 2 studies.

April 04, 2024
7 Articles

Further Reading